Grupo de Estudios en Genética y Biología Molecular (GEBIMOL), School of Biological Sciences, Universidad Pedagógica y Tecnológica de Colombia - UPTC, Tunja, Boyacá, Colombia; Population Genetics And Molecular Evolution (PGAME), Fundación Scient, Tunja, Boyacá, Colombia.
Grupo de Investigaciones Microbiológicas y Biomédicas de Córdoba (GIMBIC), School of Health Sciences, Universidad de Córdoba, Montería, Córdoba, Colombia.
Acta Trop. 2024 Jul;255:107231. doi: 10.1016/j.actatropica.2024.107231. Epub 2024 Apr 27.
Malaria remains a public health challenge. Since many control strategies have proven ineffective in eradicating this disease, new strategies are required, among which the design of a multivalent vaccine stands out. However, the effectiveness of this strategy has been hindered, among other reasons, by the genetic diversity observed in parasite antigens. In Plasmodium vivax, the Erythrocyte Binding Protein (PvEBP, also known as DBP2) is an alternate ligand to Duffy Binding Protein (DBP); given its structural resemblance to DBP, EBP/DBP2 is proposed as a promising antigen for inclusion in vaccine design. However, the extent of genetic diversity within the locus encoding this protein has not been comprehensively assessed. Thus, this study aimed to characterize the genetic diversity of the locus encoding the P. vivax EBP/DBP2 protein and to determine the evolutionary mechanisms modulating this diversity. Several intrapopulation genetic variation parameters were estimated using 36 gene sequences of PvEBP/DBP2 from Colombian P. vivax clinical isolates and 186 sequences available in databases. The study then evaluated the worldwide genetic structure and the evolutionary forces that may influence the observed patterns of genetic variation. It was found that the PvEBP/DBP2 gene exhibits one of the lowest levels of genetic diversity compared to other vaccine-candidate antigens. Four major haplotypes were shared worldwide. Analysis of the protein's 3D structure and epitope prediction identified five regions with potential antigenic properties. The results suggest that the PvEBP/DBP2 protein possesses ideal characteristics to be considered when designing a multivalent effective antimalarial vaccine against P. vivax.
疟疾仍然是一个公共卫生挑战。由于许多控制策略已被证明无法根除这种疾病,因此需要新的策略,其中设计多价疫苗尤为突出。然而,由于寄生虫抗原的遗传多样性等原因,这种策略的有效性受到了阻碍。在间日疟原虫中,红细胞结合蛋白(PvEBP,也称为 DBP2)是对 Duffy 结合蛋白(DBP)的替代配体;鉴于其与 DBP 的结构相似性,EBP/DBP2 被提议作为一种有前途的抗原纳入疫苗设计。然而,编码该蛋白的基因座内遗传多样性的程度尚未得到全面评估。因此,本研究旨在表征编码间日疟原虫 EBP/DBP2 蛋白的基因座的遗传多样性,并确定调节这种多样性的进化机制。使用来自哥伦比亚间日疟原虫临床分离株的 36 个 PvEBP/DBP2 基因序列和数据库中可用的 186 个序列,估计了几个种群内遗传变异参数。然后,该研究评估了全球遗传结构以及可能影响观察到的遗传变异模式的进化力量。结果发现,与其他候选疫苗抗原相比,PvEBP/DBP2 基因表现出最低水平的遗传多样性之一。全世界共享四个主要单倍型。对蛋白质 3D 结构和表位预测的分析确定了五个具有潜在抗原特性的区域。结果表明,PvEBP/DBP2 蛋白具有理想的特征,可在设计针对间日疟原虫的多价有效抗疟疫苗时考虑。